Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 14/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021889 | 0.88 | TSHR (0.40) | GHSRTSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL17021876 | 0.88 | TSHR (0.41) | GHSRTSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL17018571 | 0.83 | MAPK1 (0.42) | GHSRTSHRALDH1A1L3MBTL1CTSK | |
| SCHEMBL17021900 | 0.78 | PLA2G2C (0.43) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL17021888 | 0.77 | TSHR (0.41) | GHSRTSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL24058755 | 0.72 | TSHR (0.38) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL20057137 | 0.72 | TSHR (0.38) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL16561772 | 0.72 | TSHR (0.53) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL20057384 | 0.72 | TSHR (0.37) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL16774850 | 0.71 | PLA2G2C (0.49) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | PRKG1, PDE3B, PDE3A | GHSR 1729/4885TSHR 4263/4885ALDH1A1 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.